20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Apogee Therapeutics, Inc. Common Stock (APGE) operates in the BIOTECHNOLOGY industry and is headquartered in San Francisco, United States with about 261 employees. Its market capitalization is roughly $10 billion. In the fiscal year ended 2025-12-31, APGE reported $0M in revenue and ($256M) in net income.
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers.
Interactive charts & full statements →
| Income statement | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | ($1M) | ($1M) | $0M | — | — |
| Gross Margin % | — | — | — | — | — |
| Operating Income (EBIT) | ($305M) | ($286M) | ($217M) | ($93M) | ($31M) |
| Operating Margin % | — | — | — | — | — |
| Net Income | ($275M) | ($256M) | ($182M) | ($84M) | ($40M) |
| Net Margin % | — | — | — | — | — |
| EBITDA | ($273M) | ($254M) | ($182M) | ($75M) | ($40M) |
| Earnings Per Share (EPS) | $-4.44 | $-4.22 | $-3.30 | $-1.66 | $-0.79 |
| Shares Outstanding (M) | 70M | 61M | 55M | 51M | 51M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | 50.0% | — | — |
| Operating Income (EBIT) | ($92M) | ($83M) | ($78M) | ($71M) | ($73M) | ($63M) | ($76M) | ($59M) | ($44M) |
| Operating Margin % | — | — | — | — | — | — | -58370.0% | — | — |
| Net Income | ($86M) | ($74M) | ($69M) | ($65M) | ($66M) | ($55M) | ($67M) | ($49M) | ($34M) |
| Net Margin % | — | — | — | — | — | — | -51706.2% | — | — |
| EBITDA | — | ($74M) | ($69M) | ($65M) | ($66M) | ($55M) | ($67M) | ($49M) | ($34M) |
| Earnings Per Share (EPS) | $-1.14 | $-1.06 | $-1.14 | $-1.11 | $-1.13 | $-0.95 | $-1.22 | $-0.86 | $-0.60 |
| Shares Outstanding (M) | — | 70M | 61M | 59M | 58M | 58M | 55M | 57M | 57M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($235M) | ($227M) | ($171M) | ($75M) | ($16M) |
| Capital Expenditures (CapEx) | $1M | $5M | $1M | $0M | $0M |
| Free Cash Flow (FCF) | ($235M) | ($233M) | ($172M) | ($75M) | ($16M) |
| FCF Margin % | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($71M) | ($56M) | ($63M) | ($54M) | ($62M) | ($48M) | ($68M) | ($43M) | ($29M) |
| Capital Expenditures (CapEx) | — | $0M | $0M | $0M | $1M | $4M | $0M | $1M | $0M |
| Free Cash Flow (FCF) | ($71M) | ($56M) | ($63M) | ($54M) | ($63M) | ($53M) | ($68M) | ($43M) | ($29M) |
| FCF Margin % | — | — | — | — | — | — | -52088.5% | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets | $1.3B | $937M | $754M | $401M | $152M |
| Cash & Cash Equivalents | $106M | $132M | $142M | $118M | $152M |
| Total Liabilities | $141M | $33M | $37M | $21M | $10M |
| Total Debt (Short + Long-Term) | — | $4M | $3M | $1M | $0M |
| Total Shareholders' Equity | $1.2B | $904M | $717M | $380M | $142M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive APGE viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms